#targeted therapy innovation awards

[latestmarketresearchnews]

Aptamers Industry 2030 Size, Share, Business Growth, Demand and Applications

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a significant compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. Aptamers have garnered attention due to recent advancements in their generation, purification, and ability to effectively target and kill specific cells, which make them a powerful tool in therapeutic development.

The COVID-19 pandemic has presented unique challenges in the field of treatment due to the virus's high mutation rate. Currently, there are no fully effective treatments specifically targeting COVID-19 across all its variants. However, aptamers, particularly nucleic acid-based and peptide aptamers, have shown promise as a potential approach to combat COVID-19. The heightened focus on biotechnological solutions for COVID-19 treatment has spurred government and private sector initiatives to accelerate R&D in this area.

One example of government support is a contract awarded in September 2020 by the Department of Community & Economic Development, which allocated USD 320,000 to Aptagen LLC to support the research and development of a novel COVID-19 treatment using aptamers. This financial support aims to foster innovation in developing therapeutic solutions using aptamer technology.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Regional Insights:

North America Aptamers Market Trends

North America led the global aptamers market with a 44.48% share in 2022. This dominance can be attributed to several factors:

High Prevalence of Chronic Diseases: Rising rates of chronic illnesses such as cancer, cardiovascular diseases, and neurological disorders have fueled the demand for targeted therapies, boosting interest in aptamer-based treatments.

Robust Healthcare Infrastructure: North America's well-developed healthcare system supports advanced research in biotechnology and pharmaceuticals, facilitating the growth of the aptamers market.

Increased Interest in Aptamer R&D: Research laboratories and institutions in the U.S. and Canada are increasingly focusing on aptamer research to explore novel treatments and diagnostic tools.

An example of North America’s commitment to aptamer R&D is seen in Noxxon Pharma's announcement in April 2022. The company presented the results of its NOX-A12 GLORIA trial for treating brain cancer at the American Society of Clinical Oncology annual meeting, underscoring the region's significant advancements in aptamer-based therapies.

Asia Pacific Aptamers Market Trends

The Asia Pacific region is expected to witness the fastest growth in the aptamers market, with a CAGR of 26.18% during the forecast period. This rapid growth is driven by factors such as:

Approval of New Aptamer-Based Products: Regulatory approvals of aptamer-based products are accelerating market expansion. For instance, Achiko AG entered an agreement in April 2020 with the Pengurus Wilayah Nahdlatul Ulama DKI, a prominent Islamic association in Indonesia, to promote its COVID-19 diagnostic kit AptameX.

Increased Healthcare Demand: As healthcare needs grow, Asia Pacific countries, particularly China, Japan, and India, are adopting advanced technologies and investing in biotechnology.

The collaboration between Achiko AG and Pengurus Wilayah Nahdlatul Ulama DKI in Indonesia highlights the potential for aptamer-based products in diagnostic applications. This organization, which has around 90 million members, offers a significant market for innovative diagnostic tools, particularly as they address the ongoing COVID-19 pandemic.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

The global sickle cell anemia testing and screening market size was estimated at USD 425.7 million in 2024 and is projected to grow at a CAGR of 12.1% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the aptamers market are actively pursuing strategies to enhance their product offerings and expand their market presence. These strategies include:

Product Modification: Companies are refining their existing aptamer products to improve efficacy and applicability across various therapeutic areas.

New Product Approvals: Firms are seeking regulatory approvals for novel aptamer-based products to strengthen their market share.

Mergers and Acquisitions: Strategic mergers and acquisitions are helping companies expand their product portfolios and enter new regional markets.

For instance, in January 2023, Aptamer Group announced a collaboration with BaseCure Therapeutics to develop Optimer-targeted therapies. Optimer technology is designed to enhance aptamer-targeted therapeutics, allowing for more precise drug delivery to target cells. This collaboration demonstrates the potential for aptamers in therapeutic applications and reflects the ongoing trend of partnerships within the industry aimed at driving innovation and broadening the use of aptamers in medical treatments.

Key Aptamers Companies:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

Aptamers Market Analysis by Application 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a significant compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. Aptamers have garnered attention due to recent advancements in their generation, purification, and ability to effectively target and kill specific cells, which make them a powerful tool in therapeutic development.

The COVID-19 pandemic has presented unique challenges in the field of treatment due to the virus's high mutation rate. Currently, there are no fully effective treatments specifically targeting COVID-19 across all its variants. However, aptamers, particularly nucleic acid-based and peptide aptamers, have shown promise as a potential approach to combat COVID-19. The heightened focus on biotechnological solutions for COVID-19 treatment has spurred government and private sector initiatives to accelerate R&D in this area.

One example of government support is a contract awarded in September 2020 by the Department of Community & Economic Development, which allocated USD 320,000 to Aptagen LLC to support the research and development of a novel COVID-19 treatment using aptamers. This financial support aims to foster innovation in developing therapeutic solutions using aptamer technology.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Regional Insights:

North America Aptamers Market Trends

North America led the global aptamers market with a 44.48% share in 2022. This dominance can be attributed to several factors:

High Prevalence of Chronic Diseases: Rising rates of chronic illnesses such as cancer, cardiovascular diseases, and neurological disorders have fueled the demand for targeted therapies, boosting interest in aptamer-based treatments.

Robust Healthcare Infrastructure: North America's well-developed healthcare system supports advanced research in biotechnology and pharmaceuticals, facilitating the growth of the aptamers market.

Increased Interest in Aptamer R&D: Research laboratories and institutions in the U.S. and Canada are increasingly focusing on aptamer research to explore novel treatments and diagnostic tools.

An example of North America’s commitment to aptamer R&D is seen in Noxxon Pharma's announcement in April 2022. The company presented the results of its NOX-A12 GLORIA trial for treating brain cancer at the American Society of Clinical Oncology annual meeting, underscoring the region's significant advancements in aptamer-based therapies.

Asia Pacific Aptamers Market Trends

The Asia Pacific region is expected to witness the fastest growth in the aptamers market, with a CAGR of 26.18% during the forecast period. This rapid growth is driven by factors such as:

Approval of New Aptamer-Based Products: Regulatory approvals of aptamer-based products are accelerating market expansion. For instance, Achiko AG entered an agreement in April 2020 with the Pengurus Wilayah Nahdlatul Ulama DKI, a prominent Islamic association in Indonesia, to promote its COVID-19 diagnostic kit AptameX.

Increased Healthcare Demand: As healthcare needs grow, Asia Pacific countries, particularly China, Japan, and India, are adopting advanced technologies and investing in biotechnology.

The collaboration between Achiko AG and Pengurus Wilayah Nahdlatul Ulama DKI in Indonesia highlights the potential for aptamer-based products in diagnostic applications. This organization, which has around 90 million members, offers a significant market for innovative diagnostic tools, particularly as they address the ongoing COVID-19 pandemic.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

The global sickle cell anemia testing and screening market size was estimated at USD 425.7 million in 2024 and is projected to grow at a CAGR of 12.1% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the aptamers market are actively pursuing strategies to enhance their product offerings and expand their market presence. These strategies include:

Product Modification: Companies are refining their existing aptamer products to improve efficacy and applicability across various therapeutic areas.

New Product Approvals: Firms are seeking regulatory approvals for novel aptamer-based products to strengthen their market share.

Mergers and Acquisitions: Strategic mergers and acquisitions are helping companies expand their product portfolios and enter new regional markets.

For instance, in January 2023, Aptamer Group announced a collaboration with BaseCure Therapeutics to develop Optimer-targeted therapies. Optimer technology is designed to enhance aptamer-targeted therapeutics, allowing for more precise drug delivery to target cells. This collaboration demonstrates the potential for aptamers in therapeutic applications and reflects the ongoing trend of partnerships within the industry aimed at driving innovation and broadening the use of aptamers in medical treatments.

Key Aptamers Companies:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[shawntillitt]

Pediatric Cancer Research Foundation Announces Grant Recipients

In a July 2024 press release, the Pediatric Cancer Research Foundation (PCRF) announced that it had awarded 21 researchers grants. The researchers will receive over $1.9 million in grants, which will go toward developing breakthroughs in treating pediatric cancers. This year's recipients include researchers who have made groundbreaking innovations in pediatric cancer.

PCRF aims to fuel research that reduces the number of cancer-related childhood deaths. The organization funds research it believes will achieve the greatest result in addressing childhood cancers. The role that PCRF plays fills a gap for researchers who do not have a track record in discoveries and do not qualify for federal grants, which require the researcher to demonstrate they have preliminary data reflecting their research shows promise.

The PCRF will fund five new recipients and 16 researchers for ongoing projects this year. Most of the researchers are conducting their projects at world-renowned research institutes. Danielle Fragalla, CEO of PCRF, stated the review committee spent hours pouring over awardee applications to determine which projects had the most potential to advance children's cancer research. Furthermore, the organization was enthusiastic about helping research to expand understanding and find advanced methods for treating childhood cancers.

The criteria for selection, first and foremost, was that these projects had to have the chance to advance the prevention, diagnosis, or treatment of cancer and whether the researcher could jump from research to clinical application. The committee looked at the originality of the research idea and presentation clarity. They also considered the researcher's resources, such as patients and the research lab. Finally, the selection committee considered the researcher's experience, background, and investigator qualifications.

Awardees include Susan Brady-Kalnay, PhD, from Case Western Reserve University Hospital. Her research project uses magnetic resonance fingerprinting (MRF) to determine how immunotherapy treats pediatric brain tumors. Before the award, Dr. Brady-Kalnay and her team developed MRF technology that generates assessments in as little as 11 seconds. This invention is significant because, before, researchers had to wait lengthy times for imaging, with images generated not producing information on whether the progress of the tumor is related to treatment-induced side effects. This fingerprinting technology allows medical professionals to precisely track responses to therapies.

Maria Fareri's Children's Hospital's Mitchell Cairo, MD, was another 2024 PCRF Grant awardee. Dr. Cairo's project focuses on cancer genetics, tumor immunology, and childhood/adolescent-targeted treatments for hematological malignancies and tumors. Prior to the award, his team also focused on re-engineering immune cells for targeted immune therapies, stem cell biology, cancer stem cells, and regenerative therapy, among other related topics.

Brian Crompton, MD, from the Dana-Farber Cancer Institute, was approved for grant funding for his project on liquid biopsy treatment for pediatric Ewing sarcoma, a destructive bone cancer. He and his research team have developed an innovative technique for extracting and profiling tumor DNA using liquid cancer biopsy samples. This treatment is important to help physicians determine if patients are responding to treatments early, enabling them to modify treatment for better outcomes.

Children's Hospital of Philadelphia Research Institute's Thomas De Raedt, PhD, will use the PCRF award to advance his work on understanding glioma development pathways. Glioma cells are tumors found in glial brain or spinal cord cells. His research analyzes tumors, conducts cellular studies, and creates accurate mouse models.

Anat Erdreich, MD, PhD, from Children's Hospital Los Angeles, is an award recipient selected for her work in using DNA hypomethylating agents for high-grade pediatric glioma. In the preclinical stage, her work builds upon prior research that found a gene that inhibits the growth of several brain cancers. She also discovered that a drug used in low doses lengthens the survival rate in mice. Her work focuses on using this drug combined with other therapies to treat brain cancers in children.

These are just a few researchers who received PCRF funding in 2024. For an extended list of other awardees and information regarding the award, please visit pcrf-kids.org/about-pcrf/.

[mysticalpeacenut]

What’s New with Depixus? Recent Press Coverage

In the rapidly advancing world of biotechnology and drug discovery, keeping up with the latest developments is crucial for stakeholders, investors, and the scientific community. Depixus, a trailblazer in RNA targeting technology, has been making headlines recently, with significant accomplishments and milestones that underscore its commitment to innovation. This blog will explore the latest press coverage, including the recent Press Release Depixus, participation in the RNA Targeted Drug Discovery Summit, and recognition at the Ignite Award ceremony.

1. Spotlight on Recent Achievements

Depixus has garnered considerable attention in the media for its groundbreaking work in the field of RNA-targeted drug discovery. The company’s pioneering approach aims to harness the power of RNA to develop innovative therapeutics that can target diseases at a molecular level. This novel strategy is particularly significant in the fight against complex diseases, including cancer and genetic disorders, where traditional treatment modalities often fall short.

In a recent Press Release, Depixus announced exciting advancements in its research and development initiatives, highlighting their latest findings and ongoing projects. These developments have not only captured the interest of industry experts but have also been featured in various scientific publications and news outlets, emphasizing the company's role as a leader in RNA-based therapeutics.

2. Participation in the RNA Targeted Drug Discovery Summit

Another significant aspect of Depixus' recent press coverage is its active participation in the RNA Targeted Drug Discovery Summit. This prestigious event brought together thought leaders, researchers, and pharmaceutical professionals to discuss the latest trends, challenges, and opportunities in RNA-targeted therapies.

During the summit, Depixus showcased its innovative technologies and methodologies, gaining insights into how RNA can be leveraged to develop more effective drugs. The discussions revolved around various applications of RNA technology, including the potential for targeting specific RNA molecules to treat diseases that have historically been difficult to manage. Presenters from Depixus shared compelling data from their ongoing studies, illustrating how their approach could revolutionize the development of targeted therapies.

The visibility gained at this summit not only enhances Depixus' reputation within the scientific community but also reinforces its commitment to advancing RNA-based drug discovery. Attendees left the event with a deeper understanding of the transformative potential that Depixus brings to the table, further solidifying the company’s position as a key player in the industry.

3. Recognition at the Ignite Award Ceremony

As a testament to its outstanding contributions to the field, Depixus was recently honored with the Ignite Award. This accolade recognizes organizations and individuals who have made significant strides in advancing innovative solutions in biotechnology. The award ceremony brought together industry leaders and innovators, celebrating the groundbreaking work being done across the sector.

Winning the Ignite Award is not only a significant achievement for Depixus but also highlights the company’s dedication to improving health outcomes through innovative research and development. The recognition from peers in the industry serves to validate Depixus’ mission and the hard work of its dedicated team. This accolade has also been prominently featured in various press releases and media coverage, further elevating Depixus’ profile in the biotechnology space.

4. Future Directions and Impact

Looking ahead, Depixus is poised to continue its trajectory of innovation and leadership in the RNA-targeted drug discovery arena. The recent press coverage, including the latest press release, illustrates the company’s ongoing commitment to pushing the boundaries of what is possible in drug development. By focusing on the intricacies of RNA and its interactions within the body, Depixus aims to unlock new therapeutic avenues that can address unmet medical needs.

Moreover, the recognition received through the Ignite Award and the visibility gained from participating in key events like the RNA Targeted Drug Discovery Summit position Depixus favorably within the industry. These milestones will likely attract further collaborations and investments, fostering an environment ripe for scientific breakthroughs.

Conclusion

In summary, Depixus is making significant strides in the field of RNA-targeted drug discovery, as evidenced by its recent press coverage and accolades. With innovative technologies, strategic participation in industry events, and recognition for its contributions, Depixus is setting the stage for a new era in biotechnology. As the company continues to lead the way in RNA research, stakeholders can expect exciting developments that hold the promise of transforming treatment paradigms and improving patient outcomes.

For more information on how Depixus is advancing RNA-targeted drug discovery and to stay updated with our latest news, feel free to contact us today!

Reposted Blog Post URL: https://petrickzag.bcz.com/2024/10/07/depixus-recent-press-release/

[wellnessweb]

Globalization and Market Expansion in Multiple Myeloma

The Multiple Myeloma Market size was estimated at USD 24.01 Billion In 2023 & is estimated to reach USD 59.45 Billion by 2032 and increase at a compound annual growth rate of 10.6% between 2024 and 2032.The Multiple Myeloma market is characterized by a dynamic interplay of research, treatment advancements, and patient-centric care initiatives. As one of the most prevalent hematologic cancers, it continuously draws attention from pharmaceutical innovators and healthcare providers alike. Recent years have witnessed a surge in targeted therapies, immunotherapies, and personalized medicine approaches tailored to combatting its complexities. This evolving landscape not only fosters competition among biopharmaceutical companies but also emphasizes the importance of early detection and multidisciplinary treatment strategies. With ongoing clinical trials promising novel therapeutic avenues, the Multiple Myeloma market remains poised for further breakthroughs in extending patient survival and enhancing quality of life.

The Multiple Myeloma Market  research study for the term also includes a variety of business opportunities and growth potential. A business plan detailing market risks and constraints as well as the effects of various regulatory regimes is given to executives by the market research. This is carried out to assist companies in reaching their main goals and making better judgments.

Get Sample Copy Of This Report @ https://www.snsinsider.com/sample-request/3490

Market Segmentation

By Type

Chemotherapy

Monoclonal Antibody

Protease Inhibitors

Others

By Disease Type

Smoldering Multiple Myeloma

Active Multiple Myeloma

By End User

Clinics

Hospitals

Others

Regional Outlook

The geographical categories that make up the Multiple Myeloma Market  each have their own revenue, market share, sales, and growth rates. Among the important geographical areas covered in the market analysis are Europe, Asia-Pacific, South America, North America, and the Middle East and Africa. Latin America is expected to have a small market share in value, while North America is forecast to maintain its global leadership position and have a significant market share in both volume and value.

COVID-19 Impact Analysis

In the first half of 2020, the COVID-19 virus started to spread over the world, infecting millions of people and forcing major nations to implement work stoppage and foot restrictions. Nearly every area of the economy has suffered, with the exception of medical goods and equipment for life support, including the Multiple Myeloma Market .

Competitive Landscape

The competitive analysis section of the global Multiple Myeloma Market  offers details and insights on the participants. Among the details provided are information on competition, a market overview by business status, and revenue projections by region. These businesses use a variety of strategies, such as product launches, partnerships, alliances, technology advancements, and contracts, to boost market income.

Conclusion

The market research is supported by first-hand experience, qualitative and quantitative analysis by industry analysts, and comments from key market players and actors in the value chain. The study investigates parent industry trends, micro and macroeconomic data, governing factors, and market attractiveness on a segment-by-segment basis. The study also illustrates how different market factors might have a qualitative impact on market segmentation based on geography and Multiple Myeloma Market.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Flash Chromatography Market Size

Cystic Fibrosis Market Size

Cancer Biopsy Market Size

Glaucoma Therapeutics Market Size

Genomics Services Market Size

[bellaspadubai]

Unwinding Oasis: Exploring The Best Massage Services In Dubai

In the bustling metropolis of Dubai, where the pace of life can often feel relentless, finding moments of tranquility and relaxation is essential. Amidst the towering skyscrapers and vibrant cityscape lies a sanctuary of calm - the Best  massage services in dubai . From traditional techniques to innovative therapies, Dubai boasts a diverse array of massage offerings, each promising a rejuvenating escape from the daily grind. Let’s embark on a journey through the city’s finest massage services, where bliss awaits at every touch.

Thai Massage at Spa CORDON: Transport yourself to the heart of Thailand with Spa CORDON’s authentic Thai massage experience. Combining acupressure, assisted yoga postures, and rhythmic compressions, this ancient healing art promises to restore balance to both body and mind. Nestled within the luxurious surroundings of The Ritz-Carlton, Dubai, Spa CORDON offers a tranquil oasis where stress melts away and inner peace prevails.

Balinese Indulgence at The Spa, Palace Downtown: Step into a realm of opulence and serenity at The Spa, Palace Downtown, where Balinese massage reigns supreme. Drawing inspiration from the rich cultural heritage of Bali, skilled therapists utilize a blend of gentle stretches, deep tissue work, and aromatherapy to melt away tension and promote holistic wellness. Surrounded by lush gardens and the tranquil waters of the Dubai Fountain, this lavish retreat offers a sensory journey like no other.

Hot Stone Therapy at Talise Ottoman Spa: Embark on a voyage of relaxation at Talise Ottoman Spa, where hot stone therapy takes center stage. Nestled within the iconic Jumeirah Zabeel Saray, this award-winning spa offers a sensory escape inspired by the grandeur of the Ottoman Empire. Smooth, heated stones are strategically placed on the body and used to massage away stress and muscle tension, leaving you feeling deeply relaxed and rejuvenated.

Aromatherapy Bliss at SensAsia Urban Spa: Immerse yourself in the intoxicating scents of essential oils at SensAsia Urban Spa, Dubai’s pioneer of modern spa culture. With locations across the city, including The Village Mall and Emirates Golf Club, SensAsia offers a variety of indulgent massage treatments tailored to suit your needs. From calming lavender to invigorating citrus, each aromatherapy blend is carefully curated to promote relaxation, balance, and overall well-being.

Sports Massage at Dubai Herbal & Treatment Centre: For those seeking relief from sports-related injuries or muscular tension, look no further than the Dubai Herbal & Treatment Centre. Combining therapeutic techniques with natural remedies, experienced therapists provide personalized treatments to target specific areas of concern. Whether you’re an athlete pushing the limits or simply in need of relief from everyday aches and pains, this holistic approach to healing offers a path to renewed vitality and mobility.

In a city known for its luxury and extravagance, the pursuit of wellness takes on a whole new dimension. From ancient healing traditions to cutting-edge therapies, Dubai’s massage services.

[jcmarchi]

Two from MIT awarded 2024 Paul and Daisy Soros Fellowships for New Americans

New Post has been published on https://thedigitalinsider.com/two-from-mit-awarded-2024-paul-and-daisy-soros-fellowships-for-new-americans/

Two from MIT awarded 2024 Paul and Daisy Soros Fellowships for New Americans

MIT graduate student Riyam Al Msari and alumna Francisca Vasconcelos ’20 are among the 30 recipients of this year’s Paul and Daisy Soros Fellowships for New Americans. In addition, two Soros winners will begin PhD studies at MIT in the fall: Zijian (William) Niu in computational and systems biology and Russel Ly in economics.

The P.D. Soros Fellowships for New Americans program recognizes the potential of immigrants to make significant contributions to U.S. society, culture, and academia by providing $90,000 in graduate school financial support over two years.

Riyam Al Msari

Riyam Al Msari, born in Baghdad, Iraq, faced a turbulent childhood shaped by the 2003 war. At age 8, her life took a traumatic turn when her home was bombed in 2006, leading to her family’s displacement to Iraqi Kurdistan. Despite experiencing educational and ethnic discriminatory challenges, Al Msari remained undeterred, wholeheartedly embracing her education.

Soon after her father immigrated to the United States to seek political asylum in 2016, Al Msari’s mother was diagnosed with head and neck cancer, leaving Al Msari, at just 18, as her mother’s primary caregiver. Despite her mother’s survival, Al Msari witnessed the limitations and collateral damage caused by standardized cancer therapies, which left her mother in a compromised state. This realization invigorated her determination to pioneer translational cancer-targeted therapies.

In 2018, when Al Msari was 20, she came to the United States and reunited with her father and the rest of her family, who arrived later with significant help from then-senator Kamala Harris’s office. Despite her Iraqi university credits not transferring, Al Msari persevered and continued her education at Houston Community College as a Louis Stokes Alliances for Minority Participation (LSAMP) scholar, and then graduated magna cum laude as a Regents Scholar from the University of California at San Diego’s bioengineering program, where she focused on lymphatic-preserving neoadjuvant immunotherapies for head and neck cancers.

As a PhD student in the MIT Department of Biological Engineering, Al Masri conducts research in the Irvine and Wittrup labs to employ engineering strategies for localized immune targeting of cancers. She aspires to establish a startup that bridges preclinical and clinical oncology research, specializing in the development of innovative protein and biomaterial-based translational cancer immunotherapies.

Francisca Vasconcelos ’20

In the early 1990s, Francisca Vasconcelos’s parents emigrated from Portugal to the United States in pursuit of world-class scientific research opportunities. Vasconcelos was born in Boston while her parents were PhD students at MIT and Harvard University. When she was 5, her family relocated to San Diego, when her parents began working at the University of California at San Diego.

Vasconcelos graduated from MIT in 2020 with a BS in electrical engineering, computer science, and physics. As an undergraduate, she performed substantial research involving machine learning and data analysis for quantum computers in the MIT Engineering Quantum Systems Group, under the guidance of Professor William Oliver. Drawing upon her teaching and research experience at MIT, Vasconcelos became the founding academic director of The Coding School nonprofit’s Qubit x Qubit initiative, where she taught thousands of students from different backgrounds about the fundamentals of quantum computation.

In 2020, Vasconcelos was awarded a Rhodes Scholarship to the University of Oxford, where she pursued an MSc in statistical sciences and an MSt in philosophy of physics. At Oxford, she performed substantial research on uncertainty quantification of machine learning models for medical imaging in the OxCSML group. She also played for Oxford’s Women’s Blues Football team. 

Now a computer science PhD student and NSF Graduate Research Fellow at the University of California at Berkeley, Vasconcelos is a member of both the Berkeley Artificial Intelligence Research Lab and CS Theory Group. Her research interests lie at the intersection of quantum computation and machine learning. She is especially interested in developing efficient classical algorithms to learn about quantum systems, as well as quantum algorithms to improve simulations of quantum processes. In doing so, she hopes to find meaningful ways in which quantum computers can outperform classical computers.

The P.D. Soros Fellowship attracts more than 1,800 applicants annually. MIT students interested in applying may contact Kim Benard, associate dean of distinguished fellowships in Career Advising and Professional Development.

[ranakaushal]

Prof. Gopal C. Kundu, Director R&D, KIIT-Awarded Prestigious J.C. Bose National Fellowship

The Fellowship has been awarded to Prof. Kundu in recognition of his exceptional research in cancer biology, cancer stem cells, tumor immune microenvironment, nanomedicine, drug development and cancer therapy. He has made significant and innovative contributions in understanding tumor-biology, cancer stem cells, tumor-stroma interaction, angiogenesis, cancer therapeutics, biomarker development and nanomedicine. Prof. Kundu has published 128 papers in leading national and international journals and holds one US and three Indian patents. His total citations are 10,273, h-index of 58 and i-10 index of 105.

He has been elected as a Fellow of Indian National Science Academy (INSA). He is also Fellow of National Academy of Sciences, India (NASI), Indian Academy of Sciences (IAS), Royal Society of Chemistry (FRSC) and International Association of Advanced Materials (FIAAM), Sweden. He has received several national and international awards.

Prof. Kundu is determined to take research at KIIT to global recognition. His future research plans are to establish breast, prostate, skin, gall bladder and head and neck oral cancer specific Patient Derived Xenograft (PDX) models, primary cultures and cell lines from patients and PDX models and identify potential therapeutic targets and therapeutically relevant biomarkers from cell lines, PDX and patients’ specimens using genomics and proteomics approaches for the effective targeting of cancer cells and screening of new drugs, repurposing of drugs using PDX models.

He is grateful to the Founder of KIIT & KISS, Prof. Achyuta Samanta, and the Vice Chancellor of KIIT-DU, Prof. Saranjit Singh for their continuous support towards research and development at KIIT University.

[you10tubesworld]

#SkinBrightening#PicoLaserTreatment#LaserSkinCare✨ Transform your skin and unveil its true radiance with our revolutionary pigmentation treatments using Pico Laser and Green Light Laser technologies. As an award-winning aesthetic clinic recognized for excellence, we're dedicated to providing you with the highest standard of care and cutting-edge treatments that deliver remarkable results. ✨ Discover the power of advanced laser technology for combating skin pigmentation, dark spots, and uneven skin tones. Our expertly curated video takes you on an enlightening journey through the benefits and effectiveness of Pico Laser and Green Light Laser treatments, tailored to restore your skin's natural beauty and clarity. 🔹 In This Video, You'll Explore: Pico Laser Magic: Learn how Pico Laser's precise and targeted approach breaks down pigmentation for a clearer, more even complexion. The Green Light Laser Difference: Discover how Green Light Laser therapy uniquely addresses skin pigmentation, promoting a flawless skin appearance. Why Choose Us: Experience why our clinic has been celebrated as an award-winning leader in aesthetic innovations and patient satisfaction. Success Stories: Be inspired by before-and-after transformations of individuals who have reclaimed their confidence with our pigmentation treatments. Treatment Process: Gain insight into what to expect during the treatment, including preparation, the session itself, and follow-up care, all designed for your comfort and optimal results. Expert Advice: Hear from our team of specialists who share their knowledge on treating pigmentation effectively and maintaining healthy, glowing skin. 🌟 Why Watch This Video? Discover state-of-the-art solutions for skin pigmentation that go beyond traditional treatments. Learn how our award-winning clinic stands out in delivering personalized care and exceptional outcomes. Feel empowered to make an informed decision about treating pigmentation with confidence and achieving your skin goals. 📞 Take the Next Step: Are you ready to tackle pigmentation and unlock the potential of your skin? Contact us today to schedule a consultation with our skin experts. Let's create a customized treatment plan that aligns with your vision of perfect skin. 💬 We Love Hearing From You! If you have questions, thoughts, or want to share your experiences, leave a comment below. Don't forget to like, share, and subscribe for more insights into achieving flawless skin with the latest aesthetic treatments. 🔔 Stay Updated on Beauty Innovations Subscribe and hit the notification bell to keep up with the newest trends and technologies in aesthetic beauty, brought to you by our award-winning clinic.

[fitjourneydaily]

Prodentim: A Comprehensive Review of a Revolutionary Dental Product

Introduction: In today's world, dental health plays a crucial role in our overall well-being. Dental problems can often be a cause of discomfort and can even impact our confidence. This is where innovative products like Prodentim come into the picture. In this comprehensive review, we will answer important questions like "Does Prodentim work?" and "Is Prodentim a gimmick?" We will also discuss what Prodentim is, its benefits, and its ADA approval. So let's dive in and explore the world of Prodentim! What is Prodentim? Prodentim is a cutting-edge dental product that has gained significant attention for its ability to improve oral health. It is a clinically tested oral care device designed to remove plaque, tartar, and bacteria effectively. Unlike traditional dental tools, Prodentim uses ultrasonic vibrations and LED light therapy to provide a non-invasive and pain-free experience for users. This innovative technology stimulates blood circulation, promotes gum health, and helps maintain fresh breath. Does Prodentim Work? Prodentim has been extensively studied and clinically proven to be effective in maintaining good oral health. The ultrasonic vibrations generated by Prodentim's unique technology disrupt the formation of plaque and tartar, leading to cleaner and healthier teeth. The LED light therapy aids in reducing bacteria and inflammation in the gums, promoting gum health. With consistent use, Prodentim can help prevent dental issues such as cavities, gum disease, and even bad breath. Is Prodentim a Gimmick? No, Prodentim is not a gimmick. It is a result of extensive research and development by dental professionals and experts in the field of oral care. The technology behind Prodentim is backed by scientific evidence, making it a reliable dental product. Numerous satisfied users have attested to the effectiveness of Prodentim in their oral care routines. However, as with any product, individual experiences may vary. It is essential to follow the instructions and consult with a dental professional for personalized advice. Benefits of Prodentim: 1. Comprehensive oral care: Prodentim offers a 360-degree approach to maintaining optimal dental health, targeting plaque, tartar, bacteria, and gum issues. 2. Non-invasive and pain-free: The ultrasonic vibrations and LED light therapy technology used by Prodentim provide a comfortable and painless experience, suitable for all ages. 3. Time-saving: Prodentim's advanced technology ensures efficient cleaning, meaning you can achieve better oral health in less time. 4. Cost-effective: By using Prodentim, it is possible to reduce the frequency of dental visits, resulting in potential cost savings in the long run. Is Prodentim ADA Approved? Yes, Prodentim is ADA (American Dental Association) approved. The ADA is a reputable organization that ensures dental products meet the highest standards of safety and efficacy. The ADA's Seal of Acceptance awarded to Prodentim validates its ability to contribute to oral health in a safe and effective manner. Conclusion: Oral health is a vital aspect of overall well-being, and Prodentim offers an innovative and effective solution in maintaining optimal dental hygiene. With its advanced technology, non-invasive approach, and ADA approval, Prodentim proves to be a reliable dental product. By incorporating Prodentim into your oral care routine, you can take a proactive step towards a healthier and more confident smile. Discover the truth about Prodentim – its efficacy, legitimacy, and manufacturing details. Learn more about what Prodentim is and where to buy it. For additional information, visit the 'Prodentim' website. Visit the Prodentim Product Page. Read the full article

[amisiskincare]

Amisi Skincare

Website: https://www.amisi.com.au

Address: Bunya, Queensland, Australia

Amisi Skincare, located in Bunya, Queensland, offers a luxurious range of organic and natural skincare products. Founded by aromatherapist Kerry Ann Purdy, our award-winning products are handcrafted with organic seed oils, fruits, flowers, and herbal extracts. We specialize in facial treatments, body sugaring, and massage services, providing a natural alternative to skincare and beauty. Our products, including moisturizing creams, oils, serums, and cleansing gels, are vegan and crafted for various skin types, ensuring nourishment and a radiant complexion.

Facebook: https://www.facebook.com/amisiskincare/

Instagram: https://www.instagram.com/amisi_skincare/

Pinterest: https://www.pinterest.com/amisi_skincare/

Keywords: acne treatment products sensitive skin care products broad spectrum sun protection cruelty free beauty products skincare ingredients guide vegan skincare products best natural skincare products certified organic skincare natural and organic beauty products remedies for extremely dry skin skincare ingredients explained skincare routine essentials acne treatment solutions body sugaring products certified organic beauty products organic beauty products online professional facial treatments luxury skincare collections massage therapy essentials natural skincare products online skincare routine kits skincare tips and tricks effective anti aging skincare anti aging skincare solutions organic skincare options dry skin remedies online sun protection solutions australian made skincare online botanical skincare options facial treatments online plant based skincare choices ethical skincare options award winning skincare items hydrating serums for sale cleansing gels online beauty oils for skincare skin nourishment products artisan skincare creations handcrafted skincare selections skin health essentials natural glow skincare items remedies for dry skin online gentle products for sensitive skin proven skincare tips vegan friendly skincare options authentic australian made skincare botanical extracts for skincare indulgent luxury skincare body sugaring at home kits relaxing massage therapy products plant based skincare innovations peta approved cruelty free beauty ethically sourced skincare products award winning skincare collections intensive hydrating serums refreshing cleansing gels beauty oils for radiant skin deep skin nourishment artisanal skincare creations handcrafted skincare essentials proactive skin health solutions achieve a natural glow top rated natural skincare products skincare for a youthful appearance effective acne treatment options personalized skincare routines organic certification skincare gentle care for sensitive skin skincare ingredients for results sun protection for all skin types insider skincare tips cruelty free and vegan beauty ethical choices in skincare award winning skincare innovations ultra hydrating serums gentle yet effective cleansing gels beauty oils for a radiant complexion complete skin nourishment artisan skincare craftsmanship handcrafted skincare excellence comprehensive skin health solutions achieve a radiant natural glow bestselling natural skincare skincare essentials for aging gracefully targeted acne treatment products tailored skincare routines australian made organic skincare botanical wonders in skincare luxurious award winning skincare ultimate natural glow skincare

[gynaeaestheticstips]

Glow from Within: Dr. Manal Younis' Expert PRP Injection Techniques

Introduction: In the realm of aesthetic medicine, Platelet-Rich Plasma (PRP) therapy has emerged as a game-changer, promising rejuvenation and restoration by harnessing the body's natural healing processes. A luminary in the field, has revolutionized PRP injection techniques, pioneering approaches that illuminate a person's inherent radiance from within. Her meticulous methods and expertise have garnered attention for their effectiveness and transformative results.

Understanding PRP Therapy:

PRP therapy involves utilizing the patient's blood to extract a concentrated solution of platelets, growth factors, and plasma. This potent concoction holds the power to stimulate tissue repair, collagen production, and overall skin rejuvenation.

Dr. Manal Younis' approach is rooted in a comprehensive understanding of the science behind PRP therapy. She emphasizes personalized treatments tailored to individual needs, ensuring optimal results.

Innovation in Technique:

Dr. Younis' innovation lies in her refined injection techniques, honed through years of research and practice. Her approach goes beyond mere administration; it's an art form that maximizes the effectiveness of PRP.

She employs a precise method, strategically placing injections to target specific areas with varying concentrations, optimizing the revitalization process while minimizing discomfort.

Customized Treatment Plans:

A hallmark of Dr. Younis' practice is her dedication to creating bespoke treatment plans. She meticulously assesses each patient's concerns, skin type, and desired outcomes before crafting a tailored strategy.

By customizing the concentration and depth of injections, she ensures that the PRP's benefits are maximized, delivering results that align with individual goals.

Holistic Approach to Beauty:

Dr. Manal Younis champions a holistic view of beauty that extends beyond superficial aesthetics. She emphasizes the connection between inner wellness and outer radiance.

Alongside PRP therapy, she advocates for lifestyle adjustments, proper skincare, and nutritional enhancements to complement and prolong the results.

Patient-Centric Care:

Renowned for her empathetic approach, Dr. Younis prioritizes patient comfort and satisfaction. She fosters a supportive environment, taking time to educate and involve patients in their treatment journey.

Her dedication to ethical practices and transparent communication establishes trust, empowering patients to make informed decisions about their care.

Efficacy and Safety:

She commitment to safety is unwavering. Her techniques prioritize precision and adherence to stringent safety protocols, minimizing risks associated with PRP therapy.

The efficacy of her methods is evident in the remarkable transformations witnessed among her satisfied clientele, endorsing both the safety and effectiveness of her approach.

Advancing the Field:

Dr. Manal Younis' contributions extend beyond her practice. She actively engages in research, collaborating with experts to advance PRP therapy methodologies.

Her publications and presentations at conferences contribute significantly to the evolution of PRP techniques, positioning her as a thought leader in the field.

Testimonials and Recognition:

Dr. Younis' expertise has garnered acclaim from both peers and patients. Testimonials and positive reviews highlight not only the visible improvements but also the enhanced confidence and well-being experienced by those under her care.

Recognitions and awards further validate her contributions to the field, solidifying her standing as a trailblazer in PRP therapy.

The Future of Aesthetic Medicine:

Dr. Manal Younis' groundbreaking techniques underscore the promising future of aesthetic medicine. Her innovative methodologies pave the way for refined, effective, and personalized treatments that prioritize natural rejuvenation.

As technology evolves and scientific understanding deepens, her contributions will continue to shape the landscape of aesthetic procedures, setting new standards for excellence and safety.

Conclusion: Dr. Manal Younis' expertise in PRP injection techniques transcends conventional practices, unlocking the innate radiance within each patient. She expertise in PRP injection techniques for Anti Wrinkles Injection solutions transcends conventional practices, unlocking inherent radiance while effectively combating signs of aging. Her dedication to personalized care, coupled with a commitment to safety and innovation, heralds a new era in aesthetic medicine.

[universalinfo]

IONIS PHARMACEUTICALS: PIONEERING THE FUTURE OF OLIGONUCLEOTIDE THERAPEUTICS

Are you ready to embark on an exciting journey into the world of cutting-edge medical research? Today, we’re diving deep into the realm of oligonucleotide therapeutics and exploring the groundbreaking work of Ionis Pharmaceuticals. Get ready to be amazed by their innovative approach to treating a wide range of diseases using RNA-targeted drugs. Let’s begin, shall we?

Unveiling the Power of Oligonucleotide Therapeutics

Oligonucleotide therapeutics, a mouthful to pronounce but an exciting field nonetheless, holds immense potential for revolutionizing modern medicine. Ionis Pharmaceuticals, the trailblazing leader in this domain, has harnessed the power of RNA-targeted therapies to develop groundbreaking treatments.

At the forefront of their innovation is the concept of antisense technology, which involves manipulating the building blocks of genetic material to target and modulate disease-causing genes. By leveraging the natural processes within our cells, Ionis is paving the way for innovative approaches to previously untreatable diseases. With their pioneering research, Ionis is bringing the future of medicine into the present.

One of the key breakthroughs in oligonucleotide therapeutics achieved by Ionis is their ability to design molecules called antisense oligonucleotides (ASOs). These ASOs are custom-built to bind to specific RNA molecules, regulating their function and altering disease processes at the genetic level.

The versatility of ASOs allows for the development of targeted therapies for a wide range of conditions, from genetic disorders to neurological diseases and even certain types of cancer. Ionis Pharmaceuticals has truly unlocked the potential of oligonucleotide therapeutics to address unmet medical needs.

A Well-Deserved Award: Recognizing Breakthrough Research

In the ever-evolving world of scientific research, recognition plays a vital role in driving progress forward. Ionis Pharmaceuticals’ dedication to pushing the boundaries of oligonucleotide therapeutics has not gone unnoticed.

In 2019, the company received the prestigious OTS Paper of the Year Award for their publication titled “Chemical Modification of PS-ASO therapeutics reduces cellular protein-binding and Improves the therapeutic index” in Nature Biotechnology. This highly esteemed accolade recognizes the most impactful paper in the field of oligonucleotide therapeutics, shedding light on the immense value of Ionis research.

The awarded publication showcases Ionis’ commitment to basic research and highlights the significance of chemical modifications in enhancing the efficacy and safety of their antisense oligonucleotide therapies.

By reducing cellular protein binding, Ionis scientists have improved the therapeutic index, which is a measure of the balance between efficacy and toxicity. This breakthrough not only demonstrates the ingenuity of Ionis researchers but also opens new horizons for the development of even better medicines in the field of oligonucleotide therapeutics.

Ionis CEO and founder, Stanley Crooke, M.D., Ph.D., played a pivotal role as one of the contributing authors of the award-winning publication. This recognition not only reflects Ionis’ commitment to scientific excellence but also reaffirms its position as a pioneer in the field.

The Rising Star: Holly Kordasiewicz and the Young Investigator Award

Every field needs fresh faces and innovative minds to drive progress forward. The Oligonucleotide Therapeutics Society (OTS) recognizes the outstanding achievements and contributions of professional scientists through the Mary Ann Liebert, Inc. publishers Young Investigator Award.

In 2019, this prestigious honor went to Holly Kordasiewicz, Ph.D., Ionis’ executive director of neurological disease drug discovery. Dr. Kordasiewicz’s dedication to unraveling the mysteries of neurodegenerative diseases has earned her this well-deserved recognition.

Neurodegenerative diseases, such as spinal muscular atrophy, Huntington’s disease, and amyotrophic lateral sclerosis, pose immense challenges for patients and researchers alike. Dr. Kordasiewicz’s transformative antisense medicines offer hope to countless individuals affected by these devastating conditions.

Her groundbreaking research and innovative approach have shed light on potential therapeutic strategies to combat these diseases. By targeting the underlying genetic factors contributing to neurodegeneration, Dr. Kordasiewicz and her team at Ionis are pioneering new avenues for treatment.

Ionis Presentations: Unveiling the Future of Oligonucleotide Therapeutics

When it comes to showcasing its groundbreaking research, Ionis Pharmaceuticals doesn’t hold back. The 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich, Germany, provided an ideal platform for Ionis scientists to present their latest advancements in antisense technology. These presentations covered a range of topics, each shedding light on the potential of oligonucleotide therapeutics to transform the landscape of medical treatments.

On October 2019, Ionis scientists delved into the fascinating realm of RNA processing. Their presentation titled “Cleavage of pre-mRNA in the Nucleus by RNase H1-dependent Antisense Oligonucleotides Causes RNA Polymerase II Transcription Termination” highlighted the mechanisms by which antisense oligonucleotides can modulate gene expression at the transcriptional level. Understanding these intricate processes is crucial for harnessing the full potential of oligonucleotide therapeutics.

Another captivating presentation titled “Development and Characterization of AZD8701, a High-Affinity Antisense Oligonucleotide Targeting FOXP3 to Relieve Immunosuppression in Cancer” took place that year. The Ionis team showcased their efforts to tackle the challenges posed by immunosuppression in cancer.

By specifically targeting the FOXP3 gene, which plays a crucial role in immune regulation, Ionis aims to develop therapies that enhance the anti-cancer immune response. This novel approach holds immense promise for improving cancer treatment outcomes.

Moreover, the conference provided an opportunity to honor the recipients of prestigious awards. Dr. Kordasiewicz, the winner of the Young Investigator Award, delivered a captivating talk on her groundbreaking research in the treatment of neurodegenerative diseases. The recognition bestowed upon her by the OTS serves as a testament to her dedication and the potential of oligonucleotide therapeutics in addressing unmet medical needs.

Beyond the Stage: Ionis’ Poster Presentations

While oral presentations often steal the spotlight at scientific conferences, poster presentations are the unsung heroes that offer a more intimate glimpse into ongoing research.

Ionis Pharmaceuticals made sure to captivate the audience with its visually engaging and information-packed posters. These displays covered a range of topics, each shedding light on various aspects of oligonucleotide therapeutics and Ionis’ cutting-edge research. One of the posters, titled “Invalidation of GSK3B in the Pancreatic Beta Cell as a Therapeutic Target for T2D,” focused on investigating potential therapeutic strategies for type 2 diabetes (T2D).

By exploring the role of GSK3B, a protein kinase implicated in diabetes, Ionis scientists aim to identify novel approaches to modulating pancreatic beta cell function. This research represents a step forward in the quest to develop more effective treatments for T2D, a prevalent and challenging disease.

Another poster presentation titled “Improved Safety & Tolerability Profile with Ligand Directed Delivery of Antisense Oligonucleotides in Humans: An Integrated Comparison of Parent 2′-OMethoxyethyl Chimeric ASOs to the GalNAc3-Conjugates” tackled the critical issue of safety and tolerability in oligonucleotide therapeutics.

Ionis researchers explored ligand-directed delivery systems, such as GalNAc3-conjugates, to improve the safety profiles of antisense oligonucleotides. By optimizing delivery mechanisms, Ionis aims to enhance the therapeutic potential of its RNA-targeted drugs while minimizing side effects.

Additionally, Ionis presented a poster titled “Controlling Chirality of Phosphorothioates in Antisense Oligonucleotides Does Not Enhance Potency or Duration of Effect in the CNS,” which focused on the role of chirality in antisense oligonucleotides’ potency and efficacy in the central nervous system. The research aimed to explore the impact of chirality on therapeutic outcomes, providing valuable insights into the design and optimization of antisense therapies for neurological diseases.

Ionis Pharmaceuticals: A Beacon of Hope for Patients

Beyond the groundbreaking research, awards, and conference presentations, Ionis Pharmaceuticals ultimately strives to bring hope to patients facing unmet medical needs. The impact of their RNA-targeted drugs has already been felt with the first approved treatment for spinal muscular atrophy, a devastating genetic disorder that affects both children and adults.

Additionally, Ionis achieved a significant milestone with the approval of the world’s first RNA-targeted therapeutic for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. These successes exemplify Ionis’ commitment to delivering tangible solutions and transforming lives.

However, Ionis is not resting on its laurels. With a robust pipeline of over 40 novel medicines, they are tirelessly pursuing treatments for a broad range of diseases, including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases, and cancer.

Ionis’ unwavering dedication to patients, coupled with its pioneering spirit and innovative approach to oligonucleotide therapeutics, positions them as a beacon of hope in the realm of medical research.

Conclusion

One thing becomes abundantly clear: Ionis Pharmaceuticals is spearheading a revolution in modern medicine. Through their groundbreaking research, prestigious awards, and unwavering dedication to patients, Ionis has emerged as a trailblazer in the field. The potential for oligonucleotide therapeutics to transform lives is immense, and we eagerly await the next chapter in this awe-inspiring journey.

Website : https://www.hub-xchange.com/sb/ionis-pharmaceuticals-pioneering-future-oligonucleotide-therapeutics/

[shawntillitt]

PCRF Funding Supports Research to Reduce Childhood Cancer

The Pediatric Cancer Research Foundation (PCRF) is dedicated to eradicating childhood cancer by accelerating scientific breakthroughs that lead to cures. Since its inception in 1982, PCRF has continuously worked toward its mission of ensuring that no child succumbs to cancer.

PCRF focuses on funding revolutionary research aimed at developing less toxic cancer treatment regimens. The foundation strives to empower researchers across the nation whose innovative ideas hold the potential to revolutionize pediatric cancer care. Having invested over $58 million in pediatric cancer research, PCRF has significantly contributed to transformative advances in cancer treatment.

By providing crucial early-stage funding, PCRF enables researchers to prove their concepts, laying a foundation for larger grants and federal funding. This approach has propelled the cultivation of a new generation of researchers, reshaping the landscape of pediatric cancer treatment and diagnosis.

The foundation efficiently channels donated funds into impactful research endeavors within a year of receipt. Following a stringent evaluation by a panel of independent scientists and subject-matter experts, it allocates donations to pioneering projects with the potential to bring about significant breakthroughs. Grant awards are finalized and distributed to researchers during the initial quarter of the subsequent year.

Although the research grant process is straightforward, the research journey itself is complex. From the point of discovery to realizing FDA-approved treatments, scientific achievements can take from several months to decades to benefit patients. Within a rigorous research process, increased funding enables the simultaneous testing of numerous innovative concepts, with the primary aim of expediting the transition of discoveries from the laboratory to enhanced patient care. Every donation directly works toward cures and promising futures for children.

Donations made to PCRF have been pivotal in the organization’s ability to fund remarkable progress. This funding has been directly used to support research on pioneering treatments for various types of childhood cancers.

One notable milestone is the pivotal role PCRF-funded research played in curing advanced mature B cell non-Hodgkin lymphoma in children and adolescents. Through innovative therapies, toxic exposure and treatment periods have been reduced. More efficient treatment strategies enable young patients to lead healthier lives and spend less time in hospitals while undergoing therapy.

PCRF's allocation of funding for research on CART cell infusion facilitated groundbreaking treatment approaches. The development of T cells paired with genetic engineering led to the first-in-human protocol targeting leukemia. This revolutionary work paved the way for state of the art therapies harnessing the body’s immune system, driving advances in immuno-oncology.

Funding from PCRF has demonstrated the potential of immunotherapy in treating osteosarcoma, a form of bone cancer that initially develops in the cells that produce bones. This research offers hope for patients who previously had limited treatment options.

PCRF funding has also enabled diagnostic tests for JMML, an uncommon type of childhood leukemia that involves the movement of cancerous cells into tissues like the skin, lungs, and intestines. New diagnostic tests predict the likelihood of positive responses to intensive treatments and optimize patient outcomes in a disease with historically low survival rates.

PCRF's relentless pursuit of innovative breakthroughs has also contributed significantly to advances in acute myeloid leukemia (AML) treatments. Research supported by PCRF has led to the development of newer and more effective drugs, offering promising avenues to combat AML by targeting the overproduction of specific proteins.

[quinnlarrabee]

What we'll lose besides weight because of the new obesity cure

Rippling abs may no longer require a life of deprivation and misery, says science.

New drugs called GLP1-agonists, developed by people who love cake and hate exercise, claim to make you thin with just one injection each week and a bit of insurance fraud. By slowing down the rate of “gastric emptying” (which sounds like the clinical term of puking) and telling the hypothalamus not to be hungry, it prolongs feelings of fullness and reduces appetite, which gradually turns obese people into magazine centerfolds. As someone whose fragile self-worth is based primarily on my body composition, for which I’ve sacrificed all manner of edible joy, months-worth of sleep and probably several relationships, I find this pharmaceutical innovation troubling. The prospect of this drug not only eliminates the excuse I use to justify being obsessive about exercise and annoying about food, it also makes me feel like I studied my whole adult life for a test that suddenly no one even has to take. Now I know what it feels like to be a post-calculator era mathematician. I don’t remember a day when I didn’t do some form of mindless, compulsive exercise, and I regularly decline dinner invitations not just because I don’t like people but also because of the lack of control I have over what restaurants put into their hedonistic devil food. I think the world (I, especially) stand to lose more than we will gain from this weight-loss wonder-drug.

It’s true that we’ll save billions of dollars each year on healthcare, lifespans will extend, and entire continents of cotton will be spared when there is no longer a buyer for size XXXL, but let’s quantify what this miracle cure for fatness will cost us:

Yo-mamma-so-fat jokes. Yo-mamma-so-skinny jokes just aren’t as funny.

Santa Claus. Who wants to sit on the lap of a jolly skinny guy?

The cultural identity of Wisconsin.

Exciting extra-marital affairs. Why else will people stray after 7 years of marriage?

Arm rest disputes on airplanes. No more hilarious, silent, passive aggressive fights at 37,000 feet.

The revenue generated every time someone says, “super-size it” at McDonalds. How will this affect the already teetering economy?

Spanx.

France’s myopic, xenophobic perception of America.

Late night infomercials for specious diet fads.

78% of the subject matter of magazines targeted to women. What’s next – a pill for having a real orgasm with a man without months of ego-sensitive coaching, meditative fantasizing, and hidden vibrators?

Skinny mirrors.

The enduring relevance and rising value of vintage Jane Fonda VHS workout videos.

Mumus.

Sumo wrestling.

Man bras, aka bros.

Inspiring gastric bypass surgery success stories.

Daytime makeover television shows.

Academy awards given to perfectly fit actors called Brendan Fraser, who are enjoying a very brief career resurgence, for wearing fat suits in gripping, tragic films called The Whale.

Whales.

The income of unqualified / uncertified Instagram trainers and nutritionists who are just capitalizing on their own genetic lottery win.

Using being bullied for being a chubby preteen as an excuse for being emotionally stunted and eternally single, even though they didn’t have this drug when I was a chubby preteen.

Therapy.

The list of what we will inevitably lose with this miracle drug (that will make the entire world happier, healthier and wealthier) is endless, or at least goes to 24 or 25. I can only hope that the éclaire lobby pressures the FDA hard enough to discover some lethal side effect so that the world can continue to benefit from obesity and that I can continue to compensate for my personality defects with a rare 31-inch waist.  

On that personal note, I’d like you to consider what I will lose if the weight loss drug hits pharmacy shelves.

Overweight people make me feel better about my ennui. I see merry fat folks in the world, and I think, they may be happier than me, but I have cum gutters. Maybe they wake up and eat chocolate chip scones in bed with their equally plump life partner who finds their love handles endearing, because they’re good enough people to see past a few extra pounds, recounting over cups of whole milk cappuccinos their fond, shared memories of the dumplings and gravy fries they ate for dessert last night, while I wake up alone in the mocking expanse of my king sized bed (that does not have even the slightest body depression) before riding to the gym on my superficial high horse where I’ll stare at the black rubber floor while holding a plank for so long that I pop a blood vessel in my left eye so that I can fit into sample sizes and wear a speedo in Europe with American impunity. Sure, they’re better liked by everyone because they order fries for the table and have joy in their lives, but people I don’t even know ask me in domestic airport lounges for kale juicing tips when they sense how skinny and sad I am.

This drug will force me to find meaning outside of a mirror, and I’m just not ready to do that caliber of self-work. I’m not ready to distinguish myself on the talents that I’ll be forced to discover and hone when everyone has no more than 7% body fat. I want to remain a special snowflake purely thanks to my v-shaped torso, which I’ll probably be able to maintain for only another year or two. If I had the discipline and grit to do anything in life but squats, bench presses and body-judge other people, I would ask you to sign a petition demanding the end of research into drugs that eliminate obesity and level the beauty playing field so that we can focus instead on what someone looks like on the inside. In lieu of a petition, please just forward this to someone you know who spends far too much time on their abs along with the caption, “lol jokes on u.”